Evidence map›Paper›PMID 34752201›Full record

ArticleBioengineered2021

RASA4 inhibits the HIFα signaling pathway to suppress proliferation of cervical cancer cells.

Junying Chen, Jinbing Huang, Qiaoqiao Huang, Ji Li, Erling Chen, Wensheng Xu

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Junying ChenDepartment of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning City, China.
Jinbing HuangDepartment of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning City, China.
Qiaoqiao HuangDepartment of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning City, China.
Ji LiDepartment of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning City, China.
Erling ChenDepartment of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning City, China.
Wensheng XuDepartment of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning City, China.
First Affiliated Hospital of GuangXi Medical University · CNGuangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAS p21 protein activator 4 (RASA4) has been recognized as a Ca

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsCarcinoma, Squamous CellCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHeLa CellsHumansMiceMice, Inbred C57BLPrognosisras GTPase-Activating ProteinsRNA, MessengerSignal TransductionUterine Cervical NeoplasmsBasic Helix-Loop-Helix ProteinsRASA4 protein, humanras GTPase-Activating ProteinsRNA, Messengercervical squamous cell carcinomaHIFαproliferationRASA4

Identifiers

PMID34752201
PMCPMC8809920
OpenAlexW3212125905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.